RCT | Epirubicin + Paclitaxel vs Epirubicin and Cyclophosphamide followed by Paclitaxel in operable ERBB2-negative and lymph node–positive BC

Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer: A Randomized Clinical Trial – JAMA Network Open

Commentary on Twitter

RCT: Epirubicin + paclitaxel was non-inferior to the standard epirubicin + cyclophosphamide followed by paclitaxel in patients with operable HRBB2 negative and lymph nodes-positive breast cancer. https://t.co/Z672x44dQL pic.twitter.com/WdNJDtktLX

— JAMA Network Open (@JAMANetworkOpen) February 24, 2023